CUE — Cue Biopharma, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2018-01-02.
Performance
Technicals
Others in Healthcare
Measured signals that fired on CUE
| date | signal | measured base rate |
|---|---|---|
| 2026-08-17 | Cluster sale: three or more insiders insider | -0.36% over 21 days · t = -3.35 · n = 21,529 statistically distinguishable from its control group |
| 2026-07-14 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-30 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-02 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-01 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-01 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-13 | Lin Shao-Lee Chief Executive Officer | Open-market sale | 10.5K | 29.48 | 308.4K |
| 2026-08-13 | Ray Sumita Chief Legal Compliance Officer | Open-market sale | 6.4K | 30.35 | 195.5K |
| 2026-08-13 | Lin Shao-Lee Chief Executive Officer | Open-market sale | 5.4K | 27.19 | 147.5K |
| 2026-08-13 | Meluzio Michael Vincent VP, Prin. Accounting Officer | Open-market sale | 4.1K | 30.35 | 124.6K |
| 2026-08-13 | Ray Sumita Chief Legal Compliance Officer | Open-market sale | 2.4K | 29.37 | 70.0K |
| 2026-08-13 | Lin Shao-Lee Chief Executive Officer | Open-market sale | 2.4K | 28.11 | 66.8K |
| 2026-08-13 | Meluzio Michael Vincent VP, Prin. Accounting Officer | Open-market sale | 1.5K | 29.37 | 44.6K |
| 2026-08-13 | Ray Sumita Chief Legal Compliance Officer | Open-market sale | 4 | 31.13 | 125 |
| 2026-08-13 | Meluzio Michael Vincent VP, Prin. Accounting Officer | Open-market sale | 3 | 31.13 | 93 |
| 2026-08-13 | Ray Sumita Chief Legal Compliance Officer | Option exercise | 18.2K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Bleichroeder LP | 1.6M | 6.8M |
| GC Wealth Management RIA, LLC | 1.1M | 4.6M |
| VANGUARD CAPITAL MANAGEMENT LLC | 565.2K | 2.5M |
| Lion Point Capital, LP | 506.4K | 2.2M |
| GEODE CAPITAL MANAGEMENT, LLC | 244.8K | 1.1M |
| VANGUARD FIDUCIARY TRUST CO | 125.0K | 543.6K |
| Robertson Stephens Wealth Management, LLC | 110.0K | 478.5K |
| BlackRock, Inc. | 103.3K | 449.2K |
| Texas Capital Bank Wealth Management Services Inc | 91.4K | 397.4K |
| ANGELES WEALTH MANAGEMENT, LLC | 71.3K | 310.0K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 4 | 2026-08-14 | 2026-08-12 | on EDGAR ↗ |
| 144 | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| 144 | 2026-08-13 | — | on EDGAR ↗ |
| S-3 | 2026-08-12 | — | on EDGAR ↗ |
| 8-K | 2026-08-03 | 2026-07-27 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Cue Biopharma GAAP EPS of -$24.14 misses by $22.23, revenue of $7.88M beats by $5.78M · 2026-08-17
- Cue Biopharma, Inc. (CUE) filed form 8-K · 2026-08-14 · SEC EDGAR
- Cue Biopharma, Inc. (CUE) filed form 4 · 2026-08-14 · SEC EDGAR
- Cue Biopharma, Inc. (CUE) filed form 144 · 2026-08-14 · SEC EDGAR
- Cue Biopharma, Inc. (CUE) filed form 10-Q · 2026-08-14 · SEC EDGAR
- Cue Biopharma, Inc. (CUE) filed form 8-K · 2026-08-14 · SEC EDGAR
Ask the AI about CUE
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →